Staidson (Beijing) BioPharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Wang Chao

Geschäftsführender

CN¥1.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.3yrs
Eigentum des Geschäftsführers	0.08%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Recent updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected

Oct 08

Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%

Aug 03

There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump

Aug 02

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

Mar 18

Geschäftsführer

Wang Chao (42 yo)

3.3yrs

Amtszeit

CN¥1,362,100

Vergütung

Mr. Wang Chao is General Manager of Staidson (Beijing) BioPharmaceuticals Co. Ltd. from August 2021.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zhi Wen Zhou	Chairman	15.5yrs	CN¥1.30m	1.1% CN¥ 43.2m
Tao Li	Supervisor	13.8yrs	CN¥168.10k	keine Daten
Hongshan Zhang	Chairman of Supervisory Board	6.2yrs	CN¥240.00k	0.098% CN¥ 3.8m
Rong Qin Zhang	Non-Independent Director	6.2yrs	CN¥1.70m	0.21% CN¥ 8.1m
Lianchun Yang	Non-Independent Director	3.3yrs	CN¥1.60m	0.075% CN¥ 2.9m
Li Zhao	Independent Director	3.3yrs	CN¥136.80k	keine Daten
Jiajun Zhao	Independent Director	3.3yrs	CN¥136.80k	keine Daten
Hong Zheng	Employee Supervisor	3.3yrs	keine Daten	0.024% CN¥ 941.8k
Xiaoyan Wang	Director	2.2yrs	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: 300204Die Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).

Staidson (Beijing) BioPharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

High number of new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.008 loss per share (vs CN¥0.068 loss in 3Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.001 (vs CN¥0.22 loss in 2Q 2023)

Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%

There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump

New minor risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.10 loss in 1Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: CN¥0.84 loss per share (vs CN¥0.41 loss in FY 2022)

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

New major risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.14 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.41 loss per share (vs CN¥0.29 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.094 loss in 2Q 2021)

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Third quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.05 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.094 loss per share (vs CN¥0.11 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥8.02

New 90-day low: CN¥8.59

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day low: CN¥10.52

New 90-day low: CN¥10.73

First half earnings released

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥13.02